Proliferative Diabetic Retinopathy (PDR)
6
1
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
16.7%
1 terminated out of 6 trials
75.0%
-11.5% vs benchmark
33%
2 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)
A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDR
Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X
Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis